M. Poruchynsky

发表

Impaired p53 binding to importin: a novel mechanism of cytoplasmic sequestration identified in oxaliplatin-resistant cells

T. Fojo, D. Sackett, E. Komlódi-Pásztor, 2009, Oncogene.

Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin.

T. Fojo, F. Loganzo, M. Poruchynsky, 2004, Molecular cancer therapeutics.

Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins

Y. Pommier, M. Burotto, A. Fojo, 2015, Proceedings of the National Academy of Sciences.

HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.

T. Fojo, R. Andersen, J. Nieman, 2003, Cancer research.

Two forms of VP7 are involved in assembly of SA11 rotavirus in endoplasmic reticulum

A. Bellamy, H. Greenberg, M. Poruchynsky, 1988, Journal of virology.

Microtubule-disrupting chemotherapeutics result in enhanced proteasome-mediated degradation and disappearance of tubulin in neural cells.

T. Fojo, D. Sackett, M. Poruchynsky, 2010, Cancer research.

Tumor Cells Resistant to a Microtubule-Depolymerizing Hemiasterlin Analogue, HTI-286, Have Mutations in α- or β-Tubulin and Increased Microtubule Stability

E. Nogales, T. Fojo, D. Sackett, 2004 .

Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: A possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition

T. Fojo, D. Sackett, Y. Ward, 2008, Cell cycle.

Multidrug resistance

W. Telford, T. Fojo, Y. Ward, 1988 .

Immunocytochemical localization of gamma-glutamyltransferase in rat kidney with protein A-horseradish peroxidase.

M. Poruchynsky, A. Novikoff, H. Spater, 1982, Proceedings of the National Academy of Sciences of the United States of America.

Antiangiogenic (AG) Synergy with Ixabepilone (IXA): Translation of Preclinical Studies to the Clinical Setting.

J. Fargnoli, T. Fojo, H. Rugo, 2009 .

Primary sequence domains required for the retention of rotavirus VP7 in the endoplasmic reticulum

M. Poruchynsky, P. H. Atkinson, 1988, The Journal of cell biology.

Tubulin from paclitaxel-resistant cells as a probe for novel antimicrotubule agents

A. Fojo, D. Sackett, P. Giannakakou, 1997, Cancer Chemotherapy and Pharmacology.

Rotavirus protein rearrangements in purified membrane-enveloped intermediate particles

M. Poruchynsky, P. H. Atkinson, 1991, Journal of virology.

Combinations of pacliataxel and vinblastine and their effects on tublin polymerization and cellular cytotoxicity: Characterization of a synergistic schedule

T. Fojo, P. Giannakakou, M. Poruchynsky, 1998, International journal of cancer.

Detection of oligomeric and monomeric forms of P-glycoprotein in multidrug resistant cells.

V. Ling, M. Poruchynsky, 1994, Biochemistry.

Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes

D. Venzon, M. Poruchynsky, K. Hollevoet, 2016, Oncotarget.

Anticancer Agents from Unique Natural Products Sources

M. K. Harper, T. Fojo, R. Andersen, 2003 .

Bcl-xL is phosphorylated in malignant cells following microtubule disruption.

C. Rudin, T. Fojo, M. Blagosklonny, 1998, Cancer research.

Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization*

T. Fojo, Yoon-Koo Kang, D. Sackett, 1997, The Journal of Biological Chemistry.

A Phase II Clinical Trial of Ixabepilone (Ixempra; BMS-247550; NSC 710428), an Epothilone B Analog, in Patients with Metastatic Renal Cell Carcinoma

T. Fojo, S. Bates, M. Poruchynsky, 2010, Clinical Cancer Research.

Topology of the non-structural rotavirus receptor glycoprotein NS28 in the rough endoplasmic reticulum.

A. Bellamy, M. Poruchynsky, P. H. Atkinson, 1989, The EMBO journal.

Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity

S. Bates, R. Robey, M. Poruchynsky, 2003, British Journal of Cancer.

Calcium depletion blocks the maturation of rotavirus by altering the oligomerization of virus-encoded proteins in the ER

M. Poruchynsky, P. H. Atkinson, D. Maass, 1991, The Journal of cell biology.

A phase II clinical trial of BMS-247550 (ixabepilone), a microtubule-stabilizing agent in renal cell cancer.

W. Linehan, T. Fojo, S. Bates, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NSC 710428 ) , an Epothilone B Analog , in Patients with Metastatic Renal Cell Carcinoma

T. Fojo, S. Bates, M. Poruchynsky, 2010 .

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer.

S. Steinberg, T. Fojo, S. Swain, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Deletions into an NH2-terminal hydrophobic domain result in secretion of rotavirus VP7, a resident endoplasmic reticulum membrane glycoprotein

A. Bellamy, M. Poruchynsky, P. H. Atkinson, 1985, The Journal of cell biology.

Continued Tumor Reduction of Metastatic Pheochromocytoma/Paraganglioma Harboring Succinate Dehydrogenase Subunit B Mutations with Cyclical Chemotherapy

T. Fojo, A. Venkatesan, M. Poruchynsky, 2018, Cellular and Molecular Neurobiology.

Evidence for Microtubule Target Engagement in Tumors of Patients Receiving Ixabepilone

W. Linehan, T. Fojo, S. Bates, 2007, Clinical Cancer Research.

Potent inhibition of tumoral hypoxia-inducible factor 1α by albendazole

M. Poruchynsky, S. Badar, D. Morris, 2010, BMC Cancer.

A translational study of ixabepilone (BMS-247550) in renal cell cancer (RCC): Assessment of its activity and demonstration of target engagement in tumor cells

S. Bates, M. Merino, A. Fojo, 2005 .

Phase II Clinical Trial of Ixabepilone in Metastatic Cervical Carcinoma.

M. Burotto, T. Fojo, S. Bates, 2014, The oncologist.